55th Annual Meeting (October 28-November 2, 2008): A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Study of Selegiline Transdermal System (EMSAM) for the Treatment of Adolescents with Major Depression: An Interim Safety Report

Friday, October 31, 2008: 3:30 PM

River Exhibition Hall (Sheraton Chicago Hotel & Towers)

Jayasree J. Nandagopal, M.D., Psychiatry, University of Cincinnati, Cincinnati, OH

Thomas J. Hochadel, PharmD, Cognitive Research Corporation, St. Petersburg, FL

Eva Kemper, M.S.H.S., Cognitive Research Corporation, St. Petersburg, FL

Melvin Sharoky, M.D., Somerset Pharmaceuticals, Tampa, FL

Melissa L. Goodhead, B.Sc., Somerset Pharmaceuticals, Tampa, FL

Melissa P. DelBello, M.D., Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 5.31 A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Study of Selegiline Transdermal System (EMSAM) for the Treatment of Adolescents with Major Depression: An Interim Safety Report